Conventional DAPT
PreclinicalSmall molecule
Conventional DAPT is one of 40 small molecule programs targeting Coronary Artery Disease. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
223 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsPhase 3
Leqvio
NovartisPhase 3
Byetta
AstraZenecaPhase 3
Tekturna
Tibotec Pharmaceuticals, IrelandPhase 3
Zetia
OOrganon and Co
Phase 3
Xe-133
NNobilis Therapeutics Inc.
Phase 3
Ridaforolimus
Merck & Co.Phase 3
Glutamine
SanofiPhase 3
Quercetin
MMayo Clinic
Phase 3
Praluent
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Conventional DAPT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- ZZunyi Medical College